Global WholeHealth Partners Corp (GWHP) is confident in the new partnerships to produce the best COVID Antigen test on the market.
San Clemente, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- COVID Antigen testing is not going away and has become the new test and vaccine for years to come.
Global WholeHealth Partners Corp. (OTC: GWHP) offers one of the largest lines of COVID 19 tests. Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses. The strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein. Global understands the need to be ahead of the virus to conquer the virus. Now, with the vaccine, Global is offering one of the largest lines of products to fight this virus.
Global understands that this is a war on COVID 19 and we are expanding our line of products to be able to fight. With a facility now in the Philippines, Global will be able to fight the COVID War better by taking the fight to some of the regions of the world which have not been serviced.
Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.
With results in minutes versus hours or days with other diagnostic kits, the more lives that can be saved with the only FDA authorized COVID-19 POC serology Point of Care Test. With the new fingerstick test, healthcare providers can prick a patient’s finger and get results in minutes without having to wait for venous blood. Global WholeHealth Partners will be able to distribute these tests to more urgent cares, hospitals, and – to help curb the spread of CoViD19 SARS2.
As a third surge of the coronavirus threatens much of the United States, public health experts across the country say there still aren’t enough tests available to keep the virus under control. With the continual mutation of the virus, Global is keeping up with demand and keeping up with the continual changes of the virus in the R & D of the tests.
Global WholeHealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases FDA Certificate of Exportability (2260-11-2019). The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.
GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. Notably, Global offers 56 products FDA approved and many are Approved for OTC use, and 25 POC products approved by the FDA.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
Name: Charles Strongo,
CEO, Global WholeHealth Partners Corp.
Email: Sales@gwhpcorp.com Phone for Sales: 877-568-4947
This press release contains "forward-looking statements.” Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Global WholeHealth Partners Corp. (OTC: GWHP) Signs a Binding MOU With Pan Probe Biotech and AvantGen to Develop the Newest COVID-19 Antigen Test on the Market: 8K Filed on 09/21/2021
Released On: 10/25/2021
Global WholeHealth Partners Provides Competitive Pricing on Bulk COVID-19 Testing Kits and PPE Supplies
Released On: 10/24/2021
Global WholeHealth Partners Is The Trusted Provider of Wholesale PPE Supplies and COVID-19 Diagnostic Testing Kits
Released On: 10/22/2021
Order Medical Grade COVID-19 Diagnostic Testing Kits and PPE Supplies Wholesale Online from Global WholeHealth Partners
Released On: 10/20/2021
Global WholeHealth Partners Corp (OTC: GWHP) Proudly Announces Its New Manufacturing Facility Which is Able to Triple the Production Volume for the Potential Sales from Walmart, Amazon, eBay and Shopify as Stated in the 8K Filing 08/03/2021
Released On: 10/19/2021
With COVID-19 Vaccination Rates Increasing Global WholeHealth Partners Continues To Source Premium PPE Supplies and Testing Kits
Released On: 10/18/2021
Global WholeHealth Partners Sources Superior PPE Supplies and COVID-19 Diagnostic Testing Kits Available for Wholesale Purchase
Released On: 10/16/2021
Global WholeHealth Partners Corp. (OTC: GWHP), is Approved to Sell Through Walmart, Amazon, eBay and Shopify as Stated in the 8K Filing 08/03/2021; Global's Newly Designed Tests Are Now Ready for the Launch into the Retail Marketplace
Released On: 10/14/2021
Purchase Superior COVID-19 Diagnostic Testing Kits And Personal Protective Equipment Online from Global WholeHealth Partners
Released On: 10/14/2021
Global WholeHealth Partners Corp. (OTC: GWHP) Has Been Approved to Sell Its Products Through Walmart and Amazon as Stated in the 8K Filing 08/03/2021; Global's Newly Designed Tests Are Now Ready for the Launch Into the Retail Marketplace
Released On: 10/12/2021
GWHP Corp Sources Wholesale PPE Supplies and COVID 19 Testing Kits In The Age of Coronavirus and Rising COVID-19 Cases
Released On: 10/10/2021
Order Bulk PPE Supplies and COVID 19 Diagnostic Testing Kits from Global WholeHealth Partners
Released On: 10/4/2021
Shop Wholesale PPE Supplies and COVID-19 Tests Available from GWHP Corp Online Today
Released On: 9/30/2021
Global WholeHealth Partners Corp (OTC: GWHP) Partners With Pan Probe Biotech and AvantGen to Develop the Newest COVID19 Antigen Test on the Market; 8k Filed on 09/21/2021
Released On: 9/29/2021
GWHP Continues to Source COVID-19 Tests and PPE Supplies As The Delta Variant Continues to Spread
Released On: 9/27/2021
Partnerships with Key Players Enables GWHP Corp To Source PPE Supplies and COVID-19 Diagnostic Testing Kits
Released On: 9/14/2021
Global WholeHealth Partners Corp (OTC:GWHP) Now Able to Sell Through Shopify’s Multibillion Dollar Online Platform as Stated in 8k Filing 08/05/21
Released On: 9/14/2021
Global WholeHealth Partners Provides Wholesale PPE Supplies and COVID-19 Diagnostic Testing Kits
Released On: 9/12/2021